AR085301A1 - Polimorfismos de un solo nucleotido en el promotor del gen vegfa y su uso como marcadores predictivos para tratamientos anti-vegf - Google Patents

Polimorfismos de un solo nucleotido en el promotor del gen vegfa y su uso como marcadores predictivos para tratamientos anti-vegf

Info

Publication number
AR085301A1
AR085301A1 ARP120100572A ARP120100572A AR085301A1 AR 085301 A1 AR085301 A1 AR 085301A1 AR P120100572 A ARP120100572 A AR P120100572A AR P120100572 A ARP120100572 A AR P120100572A AR 085301 A1 AR085301 A1 AR 085301A1
Authority
AR
Argentina
Prior art keywords
vegfa
promoter
single nucleotide
polymorphisms
gen
Prior art date
Application number
ARP120100572A
Other languages
English (en)
Inventor
Blondel Marielle Chiron
Emmanuelle Cousin
Jean Deleuze
Jennifer Franois-Dreymann
Sandrine Mace
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of AR085301A1 publication Critical patent/AR085301A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La presente se refiere al tratamiento y al diagnóstico de un grupo de pacientes que presentan alelos específicos de polimorfismos de un solo nucleótido en la región promotora del gen VEGFA. Estos pacientes responden mejor a Aflibercept y es más probable que sean tratados eficazmente con terapia anti-VEGF.Reivindicación 1: Método de diagnóstico para determinar si es probable que un paciente ofrezca una respuesta positiva a terapia anti-VEGF en el que dicho método comprende la etapa de detectar la presencia de al menos un polimorfismo de nucleótido en la secuencia promotora del gen que codifica VEGFA (SEQ ID Nº 1) aislada de dicho paciente.
ARP120100572A 2011-02-23 2012-02-22 Polimorfismos de un solo nucleotido en el promotor del gen vegfa y su uso como marcadores predictivos para tratamientos anti-vegf AR085301A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11305188 2011-02-23

Publications (1)

Publication Number Publication Date
AR085301A1 true AR085301A1 (es) 2013-09-18

Family

ID=44071008

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120100572A AR085301A1 (es) 2011-02-23 2012-02-22 Polimorfismos de un solo nucleotido en el promotor del gen vegfa y su uso como marcadores predictivos para tratamientos anti-vegf

Country Status (6)

Country Link
US (1) US20130330341A1 (es)
EP (1) EP2678441B1 (es)
AR (1) AR085301A1 (es)
AU (1) AU2012228544B2 (es)
UY (1) UY33919A (es)
WO (1) WO2012123227A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
LT3170005T (lt) 2014-07-18 2019-07-10 Sanofi Paciento, įtariamo, kad serga vėžiu, gydymo afliberceptu rezultato prognozavimo būdas
IL260323B1 (en) 2015-12-30 2024-09-01 Kodiak Sciences Inc Antibodies and their conjugates
EA037406B1 (ru) * 2016-01-25 2021-03-25 Санофи Способ прогнозирования результата лечения афлиберцептом пациента, предположительно страдающего от рака, посредством измерения уровня биомаркера в плазме крови
US12071476B2 (en) 2018-03-02 2024-08-27 Kodiak Sciences Inc. IL-6 antibodies and fusion constructs and conjugates thereof
US11912784B2 (en) 2019-10-10 2024-02-27 Kodiak Sciences Inc. Methods of treating an eye disorder

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474796A (en) * 1991-09-04 1995-12-12 Protogene Laboratories, Inc. Method and apparatus for conducting an array of chemical reactions on a support surface
US20030092019A1 (en) * 2001-01-09 2003-05-15 Millennium Pharmaceuticals, Inc. Methods and compositions for diagnosing and treating neuropsychiatric disorders such as schizophrenia
RU2482491C2 (ru) * 2007-11-30 2013-05-20 Дженентек, Инк. Vegf полиморфизм и анти-ангиогенезная терапия
SI2540843T1 (sl) * 2008-11-05 2014-10-30 Genentech, Inc. Genetski polimorfizmi in starostna degeneracija makule
WO2010124264A2 (en) * 2009-04-24 2010-10-28 University Of Southern California Genetic variants in angiogenesis pathway associated with clinical outcome

Also Published As

Publication number Publication date
AU2012228544A1 (en) 2013-05-02
WO2012123227A1 (en) 2012-09-20
EP2678441A1 (en) 2014-01-01
AU2012228544B2 (en) 2015-06-11
EP2678441B1 (en) 2017-10-18
US20130330341A1 (en) 2013-12-12
UY33919A (es) 2012-09-28

Similar Documents

Publication Publication Date Title
AR085301A1 (es) Polimorfismos de un solo nucleotido en el promotor del gen vegfa y su uso como marcadores predictivos para tratamientos anti-vegf
Bocchio-Chiavetto et al. Blood microRNA changes in depressed patients during antidepressant treatment
ES2666282T3 (es) Métodos y composiciones para evaluar a pacientes con fallo reproductivo utilizando microARN derivado de célula inmune
Matthes et al. Tryptophan hydroxylase as novel target for the treatment of depressive disorders
AR111487A1 (es) Métodos para predecir la falta de respuesta a un tratamiento anti-tnf en sujetos con enfermedad inflamatoria intestinal
NZ597793A (en) Process for the identification of compounds for treating cancer
AR085910A1 (es) Anticuerpo del factor tisular humano y usos de este
NZ581742A (en) Biomarkers for predicting anti-tnf responsiveness or non-responsiveness
AR088294A1 (es) Determinacion de polimorfismos de un nucleotido simple utiles para predecir la respuesta clinica al acetato de glatiramero
UY35790A (es) Marcadores genéticos que predicen la respuesta al acetato de glatiramer
Nygaard et al. Birth cohort differences in the prevalence of longevity-associated variants in APOE and FOXO3A in Danish long-lived individuals
CY1120057T1 (el) Μοριακη γενετικη προσεγγιση της θεραπειας και διαγνωσης της εξαρτησης απο το αλκοολ και τα ναρκωτικα
Forand et al. Combined treatment with peptide-conjugated phosphorodiamidate morpholino oligomer-PPMO and AAV-U7 rescues the severe DMD phenotype in mice
NZ602551A (en) Genetic marker for the diagnosis of dementia with lewy bodies
Tencomnao et al. No relationship found between-1438A/G polymorphism of the serotonin 2A receptor gene (rs6311) and major depression susceptibility in a northeastern Thai population
US11591597B2 (en) MicroRNAs as therapeutic targets for ischemic stroke
WO2011028880A3 (en) Methods for enhancing genome stability and telomere elongation in embryonic stem cells
CN102808030A (zh) 单核苷多态性rs3888188在检测结核病易感性中的应用
Ghafouri-Fard et al. The key roles of non-coding RNAs in the pathophysiology of hypertension
GB201105584D0 (en) Cancer methods
MX2016012718A (es) Determinación de polimorfismos de un solo nucleótido útil para predecir la respuesta para rasagilina.
El-Tarras et al. Association between polymorphisms of SLC6A3 and DRD1 genes and autism among Saudi Arabia Taif population using PCR-restriction fragment length polymorphism (PCR-RFLP)
Pan et al. MicroRNA-301b and its target gene synaptosome-associated protein 91 as important modulators in esophageal cancer: functional experiments [RETRACTED]
AR104348A1 (es) Polimorfismos de un solo nucleótido seleccionados que son predictivos de respuestas al acetato de glatirámero
Guo et al. Association between XRCC3 Thr241Met polymorphism and risk of osteosarcoma in a Chinese population

Legal Events

Date Code Title Description
FA Abandonment or withdrawal